206 related articles for article (PubMed ID: 25310853)
21. Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution.
Parker K; Gallop-Evans E; Hanna L; Adams M
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):140-6. PubMed ID: 18922646
[TBL] [Abstract][Full Text] [Related]
22. Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy.
Lin G; Yang LY; Lin YC; Huang YT; Liu FY; Wang CC; Lu HY; Chiang HJ; Chen YR; Wu RC; Ng KK; Hong JH; Yen TC; Lai CH
Eur Radiol; 2019 Feb; 29(2):556-565. PubMed ID: 30051142
[TBL] [Abstract][Full Text] [Related]
23. Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases.
Kim JY; Kim JY; Kim JH; Yoon MS; Kim J; Kim YS
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):741-7. PubMed ID: 22898382
[TBL] [Abstract][Full Text] [Related]
24. Californium-252 neutron brachytherapy combined with external pelvic radiotherapy plus concurrent chemotherapy for cervical cancer: a retrospective clinical study.
Qian S; Ye L; Tian YH; Wang LG; Huang ZP; Li F; Hou B; Song N; Chen J; Liu Y; Liu X; Zhou T
Chin J Cancer; 2017 Feb; 36(1):24. PubMed ID: 28245859
[TBL] [Abstract][Full Text] [Related]
25. Nomograms predicting survival and patterns of failure in patients with cervical cancer treated with concurrent chemoradiotherapy: A special focus on lymph nodes metastases.
Wang W; Liu X; Meng Q; Zhang F; Hu K
PLoS One; 2019; 14(4):e0214498. PubMed ID: 30986236
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for pelvic and distant recurrence in locally advanced cervical cancer.
Queiroz ACM; Fabri V; Mantoan H; Sanches SM; Guimarães APG; Ribeiro ARG; da Nogueira Silveira Lima JP; Chen MJ; Baiocchi G; da Costa AABA
Eur J Obstet Gynecol Reprod Biol; 2019 Apr; 235():6-12. PubMed ID: 30771718
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in definitive radiotherapy of uterine cervical cancer.
Yalman D; Aras AB; Ozkök S; Duransoy A; Celik OK; Ozsaran Z; Haydaroğlu A
Eur J Gynaecol Oncol; 2003; 24(3-4):309-14. PubMed ID: 12807246
[TBL] [Abstract][Full Text] [Related]
29. Magnetic resonance imaging after external beam radiotherapy and concurrent chemotherapy for locally advanced cervical cancer helps to identify patients at risk of recurrence.
Angeles MA; Baissas P; Leblanc E; Lusque A; Ferron G; Ducassou A; Martínez-Gómez C; Querleu D; Martinez A
Int J Gynecol Cancer; 2019 Mar; 29(3):480-486. PubMed ID: 30712019
[TBL] [Abstract][Full Text] [Related]
30. Tumor Shrinkage During Chemoradiation in Locally Advanced Cervical Cancer Patients: Prognostic Significance, and Impact for Image-Guided Adaptive Brachytherapy.
Schernberg A; Bockel S; Annede P; Fumagalli I; Escande A; Mignot F; Kissel M; Morice P; Bentivegna E; Gouy S; Deutsch E; Haie-Meder C; Chargari C
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):362-372. PubMed ID: 29920324
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
Lim A; Sia S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
[TBL] [Abstract][Full Text] [Related]
32. Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
Liu J; Tang G; Zhou Q; Kuang W
Radiat Oncol; 2022 Aug; 17(1):142. PubMed ID: 35978412
[TBL] [Abstract][Full Text] [Related]
33. Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study.
Guo Q; Sun Y; Kong E; Rao L; Chen J; Wu Q; Zhang T; Liu N; Li M; Sun L
Medicine (Baltimore); 2020 Mar; 99(11):e19372. PubMed ID: 32176061
[TBL] [Abstract][Full Text] [Related]
34. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer.
Contreras J; Srivastava A; Chundury A; Schwarz JK; Markovina S; Thaker PH; Massad LS; Mutch DG; Powell MA; Grigsby PW; Lin AJ
Int J Gynecol Cancer; 2020 Aug; 30(8):1157-1161. PubMed ID: 32527770
[TBL] [Abstract][Full Text] [Related]
36. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
[TBL] [Abstract][Full Text] [Related]
37. Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy.
Robin TP; Amini A; Schefter TE; Behbakht K; Fisher CM
Brachytherapy; 2016; 15(6):845-850. PubMed ID: 27720204
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy of alternating chemoradiotherapy by conformal radiotherapy combined with intracavitary brachytherapy for high-risk cervical cancer.
Hirata K; Kodaira T; Tomita N; Ohshima Y; Ito J; Tachibana H; Nakanishi T; Fuwa N
Jpn J Clin Oncol; 2014 Jun; 44(6):556-63. PubMed ID: 24755546
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of extended-field irradiation and intracavitary brachytherapy combined with weekly cisplatin chemosensitization for IB2-IIIB cervical cancer with positive paraaortic or high common iliac lymph nodes: a retrospective review.
Kuji S; Hirashima Y; Komeda S; Tanaka A; Abe M; Takahashi N; Takekuma M; Asakura H; Harada H; Nishimura T
Int J Clin Oncol; 2014 Apr; 19(2):341-7. PubMed ID: 23546545
[TBL] [Abstract][Full Text] [Related]
40. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
